SPOTLIGHT: Talecris may be sold

Almost a year after filing plans for a $1 billion IPO for Talecris Biotherapeutics, Cerberus and partner Ampersand Ventures may instead pursue a sale of the blood plasma product business. And Australia's CSL may be in the running. The blood plasma product business has been rapidly consolidating. Talecris said last year that three companies controlled 82 percent of the U.S. market. Report

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.